Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;27(1):219-227.
doi: 10.1007/s00520-018-4316-9. Epub 2018 Jun 23.

Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada

Winson Y Cheung  1 , Michelle K White  2 , Martha S Bayliss  3 , Angela Stroupe  4 , Andrew Lovley  3 , Bellinda L King-Kallimanis  4 , Kathryn Lasch  4
Affiliations

Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada

Winson Y Cheung et al. Support Care Cancer. 2019 Jan.

Abstract

Background: Little is known on the impact of emerging treatments for advanced melanoma (stages III and IV) on patients' functioning and well-being. The objective of this study was to describe the patient-reported treatment-related symptom (TRS) burden in advanced melanoma.

Method: Twenty-nine in-depth, qualitative interviews were conducted among adult patients with advanced melanoma in Canada using a semi-structured interview method. Interviews were transcribed verbatim, and key concepts were identified using a grounded theory analytic approach.

Results: The 29 patients reported 13 unique treatment journeys involving the following drug therapy categories: cytotoxic chemotherapies, CTLA-4 inhibitors, BRAF or MEK inhibitors, and PD-1 inhibitors. Patients typically underwent multiple treatment episodes over time. Common TRSs included nausea, fatigue, diarrhea or constipation, and skin rashes. Patients described these as impacting their physical functioning, ability to perform activities of daily living, social functioning, and overall quality of life.

Conclusion: Our findings provide a description of the patient's experience with treatment for advanced melanoma. Our sample included patients typically diagnosed in mid-life, facing an urgent sequence of medical procedures and a pharmacological treatment journey that was burdensome. There is a need for less toxic and more efficacious treatments earlier in the patient journey to alleviate the impact of advanced melanoma treatment on patients' health-related quality of life.

Keywords: Burden of treatment; Cancer; Health-related quality of life; Melanoma; Patient interviews; Patient-reported; Qualitative; Treatment-related symptoms.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. American Cancer Society . Cancer Facts and Figures 2017. Atlanta: American Cancer Society; 2017.
    1. National Cancer Institute SEER Cancer Stat Facts: Melanoma of the Skin. https://seer.cancer.gov/statfacts/html/melan.html. Accessed 23 Feb 2017
    1. Canadian Cancer Society’s Advisory Committee on Cancer Statistics . Canadian Cancer Statistics 2016. Toronto: Canadian Cancer Society; 2016.
    1. Ryerson AB, Eheman CR, Altekruse SF, et al. Annual Report to the Nation on the Status of Cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312–1337. doi: 10.1002/cncr.29936. - DOI - PMC - PubMed
    1. Manola J, Atkins M, Ibrahim J, et al. Prognostic factors in metastatic melanoma: a pooled analysis of eastern cooperative oncology group trials. JCO. 2000;18(22):3782–3793. doi: 10.1200/JCO.2000.18.22.3782. - DOI - PubMed

MeSH terms